Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells

Journal of Pharmacology and Experimental Therapeutics

Volumn 329, Issue 3, 2009, Pages 1063-1070

  Yip Schneider, Michele T ^a   Klein, Patrick J ^a   Wentz, Sabrina C ^a   Zeni, Amer ^a   Menze, Alex ^a   Schmidt, C Max ^a,b,c  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c RICHARD L ROUDEBUSH VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE INHIBITOR; PD 184161; PROTEIN KINASE INHIBITOR; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RESISTANCE; CELL STRAIN HEPG2; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PRIORITY JOURNAL;

ANILINE COMPOUNDS; APOPTOSIS; BENZAMIDES; BUTADIENES; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NITRILES; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-RAF; RAS PROTEINS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANS-ACTIVATORS; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION; VIRAL REGULATORY AND ACCESSORY PROTEINS;

EID: 66749155533     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.108.147306     Document Type: Article

References (40)

1. Allen LF, Sebolt-Leopold J, and Meyer MB (2003) CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK). Semin Oncol 30:105-116. (Pubitemid 37433401)
2. Burroughs A, Hochhauser D, and Meyer T (2004) Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum. Lancet Oncol 5:409-418. (Pubitemid 38878044)
3. Bush JA and Li G (2002) Cancer chemoresistance: the relationship between p53 and multidrug transporters. Int J Cancer 98:323-330. (Pubitemid 34188673)
4. Carr BI (2004) Hepatocellular carcinoma: current management and future trends. Gastroenterology 127:S218-224.
5. Duesbery NS, Webb CP, and Vande Woude GF (1999) MEK wars, a new front in the battle against cancer. Nat Med 5:736-737. (Pubitemid 29318603)
6. El-Serag HB (2004) Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 127:S27-34.
7. El-Serag HB, Davila JA, Petersen NJ, and McGlynn KA (2003) The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 139:817-823.
8. English JM and Cobb MH (2002) Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci 23:40-45. (Pubitemid 34135974)
9. Fukuda K, Tsuchihara K, Hijikata M, Nishiguchi S, Kuroki T, and Shimotohno K (2001) Hepatitis C virus core protein enhances the activation of the transcription factor, Elk1, in response to mitogenic stimuli. Hepatology 33:159-165. (Pubitemid 32016898)
10. Gomaa AI, Khan SA, Toledano MB, Waked I, and Taylor-Robinson SD (2008) Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol 14:4300-4308.
11. Harada K, Shiota G, and Kawasaki H (1999) Transforming growth factor-alpha and epidermal growth factor receptor in chronic liver disease and hepatocellular carcinoma. Liver 19:318-325. (Pubitemid 29359097)
12. Höpfner M, Sutter AP, Huether A, Schuppan D, Zeitz M, and Scherübl H (2004) Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma. J Hepatol 41:1008-1016. (Pubitemid 39575669)
13. Huynh H, Nguyen TT, Chow KH, Tan PH, Soo KC, and Tran E (2003) Overexpression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis. BMC Gastroenterol 3:19. (Pubitemid 38681501)
14. Huynh H, Soo KC, Chow PK, and Tran E (2007) Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma. Mol Cancer Ther 6:138-146. (Pubitemid 46206676)
15. Hwang YH, Choi JY, Kim S, Chung ES, Kim T, Koh SS, Lee B, Bae SH, Kim J, and Park YM (2004) Over-expression of c-raf-1 proto-oncogene in liver cirrhosis and hepatocellular carcinoma. Hepatol Res 29:113-121. (Pubitemid 38667508)
16. Ito Y, Sasaki Y, Horimoto M, Wada S, Tanaka Y, Kasahara A, Ueki T, Hirano T, Yamamoto H, Fujimoto J, et al. (1998) Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma. Hepatology 27:951-958. (Pubitemid 28160479)
17. Klein PJ, Schmidt CM, Wiesenauer CA, Choi JN, Gage EA, Yip-Schneider MT, Wiebke EA, Wang Y, Omer C, and Sebolt-Leopold JS (2006) The effects of a novel MEK inhibitor PD184161 on MEK-ERK signaling and growth in human liver cancer. Neoplasia 8:1-8.
18. Kohno M and Pouyssegur J (2003) Pharmacological inhibitors of the ERK signaling pathway: application as anticancer drugs. Prog Cell Cycle Res 5:219-224.
19. Llovet JM, Burroughs A, and Bruix J (2003) Hepatocellular carcinoma. Lancet 362:1907-1917. (Pubitemid 37518510)
20. McKillop IH, Schmidt CM, Cahill PA, and Sitzmann JV (1997) Altered expression of mitogen-activated protein kinases in a rat model of experimental hepatocellular carcinoma. Hepatology 26:1484-1491. (Pubitemid 27520013)
21. McKillop IH, Schmidt CM, Cahill PA, and Sitzmann JV (1999a) Altered Gq/G11 guanine nucleotide regulatory protein expression in a rat model of hepatocellular carcinoma: role in mitogenesis. Hepatology 29:371-378. (Pubitemid 29088439)
22. McKillop IH, Schmidt CM, Cahill PA, and Sitzmann JV (1999b) Inhibitory guanine nucleotide regulatory protein activation of mitogen-activated protein kinase in experimental hepatocellular carcinoma in vitro. Eur J Gastroenterol Hepatol 11:761-768. (Pubitemid 29349021)
23. McKillop IH, Vyas N, Schmidt CM, Cahill PA, and Sitzmann JV (1999c) Enhanced Gi-protein-mediated mitogenesis following chronic ethanol exposure in a rat model of experimental hepatocellular carcinoma. Hepatology 29:412-420. (Pubitemid 29088444)
24. Moon WS, Chang KJ, Majumdar AP, and Tarnawski AS (2004) Reduced expression of epidermal growth factor receptor-related protein in hepatocellular carcinoma: implications for cancer growth. Digestion 69:219-224. (Pubitemid 39140467)
25. Olthoff KM (1998) Surgical options for hepatocellular carcinoma: resection and transplantation. Liver Transpl Surg 4:S98-104.
26. Schmidt CM, McKillop IH, Cahill PA, and Sitzmann JV (1997a) Alterations in guanine nucleotide regulatory protein expression and activity in human hepatocellular carcinoma. Hepatology 26:1189-1194. (Pubitemid 27509302)
27. Schmidt CM, McKillop IH, Cahill PA, and Sitzmann JV (1997b) Increased MAPK expression and activity in primary human hepatocellular carcinoma. Biochem Biophys Res Commun 236:54-58. (Pubitemid 27341838)
28. Schmidt CM, McKillop IH, Cahill PA, and Sitzmann JV (1999) The role of cAMPMAPK signalling in the regulation of human hepatocellular carcinoma growth in vitro. Eur J Gastroenterol Hepatol 11:1393-1399. (Pubitemid 30009345)
29. Schmidt CM, Wang Y, and Wiesenauer C (2003) Novel combination of cyclooxygenase- 2 and MEK inhibitors in human hepatocellular carcinoma provides a synergistic increase in apoptosis. J Gastrointest Surg 7:1024-1033. (Pubitemid 37524070)
30. Schwarz M, Buchmann A, and Bock KW (1995) Role of cell proliferation at early stages of hepatocarcinogenesis. Toxicol Lett 82-83:27-32. (Pubitemid 26054692)
31. Sebolt-Leopold JS (2004) MEK inhibitors: a therapeutic approach to targeting the Ras-MAP kinase pathway in tumors. Curr Pharm Des 10:1907-1914. (Pubitemid 38647576)
32. Sebolt-Leopold JS and Herrera R (2004) Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 4:937-947. (Pubitemid 39626217)
33. Seger R and Krebs EG (1995) The MAPK signaling cascade. FASEB J 9:726-735.
34. Stahl S, Ittrich C, Marx-Stoelting P, Köhle C, Altug-Teber O, Riess O, Bonin M, Jobst J, Kaiser S, Buchmann A, et al. (2005) Genotype-phenotype relationships in hepatocellular tumors from mice and man. Hepatology 42:353-361. (Pubitemid 41061088)
35. Tannapfel A, Sommerer F, Benicke M, Katalinic A, Uhlmann D, Witzigmann H, Hauss J, and Wittekind C (2003) Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut 52:706-712. (Pubitemid 36528874)
36. Tarn C, Lee S, Hu Y, Ashendel C, and Andrisani OM (2001) Hepatitis B virus X protein differentially activates RAS-RAF-MAPK and JNK pathways in X-transforming versus non-transforming AML12 hepatocytes. J Biol Chem 276:34671-34680. (Pubitemid 37384463)
37. Tsutsumi T, Suzuki T, Moriya K, Shintani Y, Fujie H, Miyoshi H, Matsuura Y, Koike K, and Miyamura T (2003) Hepatitis C virus core protein activates ERK and p38 MAPK in cooperation with ethanol in transgenic mice. Hepatology 38:820-828. (Pubitemid 37221665)
38. van Biesen T, Hawes BE, Luttrell DK, Krueger KM, Touhara K, Porfiri E, Sakaue M, Luttrell LM, and Lefkowitz RJ (1995) Receptor-tyrosine-kinase- and G beta gammamediated MAP kinase activation by a common signalling pathway. Nature 376:781-784.
39. Wang Y, Van Becelaere K, Jiang P, Przybranowski S, Omer C, and Sebolt-Leopold J (2005) A role for K-ras in conferring resistance to the MEK inhibitor, CI-1040. Neoplasia 7:336-347. (Pubitemid 40664223)
40. Wiesenauer CA, Yip-Schneider MT, Wang Y, and Schmidt CM (2004) Multiple anticancer effects of blocking MEK-ERK signaling in hepatocellular carcinoma. J Am Coll Surg 198:410-421. (Pubitemid 38283732)